China has just approved the start of clinical trials in humans in an initial phase for two experimental vaccines aimed at preventing new infections by the new coronavirus.
Experimental vaccines are being developed by a unit of Sinovac Biotech (SVA.O) based in Beijing and by the Wuhan Biological Products Institute, a subsidiary of China’s state-owned national pharmaceutical group.
Already last March China gave the green light to another clinical trial for a candidate for the coronavirus vaccine developed by the Chinese Academy of Military Medical Sciences and the signature of Hong Kong CanSino Bio Biotechnology (6185.HK), and days later the company of USA Modern (MRNA.O) announced that it had begun human testing for its vaccine designed in collaboration with US National Institutes of Health USA
The vaccine approved in March is already in phase II and is being tested in 500 volunteers, as reported yesterday by the state newspaper China Daily.
The vaccine is developed using methods of genetic engineering and it is used to prevent diseases caused by new coronavirus infections.
The first phase of the clinical trial of the vaccine focused on its security, while the second phase seeks to demonstrate in its effectiveness. Unlike the first phase, the second phase recruited more participants and introduced a placebo control group.